德纳维制药(DVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DVAX 德纳维制药

盘前交易 02-05 07:56:14 EST

15.51

+0.03

+0.19%

盘前15.51

+0.000.00%

07:42 EST

最高15.59	最低15.47	成交量448.37万
今开15.48	昨收15.48	日振幅0.78%
总市值17.68亿	流通市值17.68亿	总股本1.14亿
成交额6,951万	换手率3.93%	流通股本1.14亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DVAX","market":"US","secType":"STK","nameCN":"德纳维制药","latestPrice":15.51,"timestamp":1770238800000,"preClose":15.48,"halted":0,"volume":4483678,"hourTrading":{"tag":"盘前","latestPrice":15.51,"preClose":15.51,"latestTime":"07:42 EST","volume":557,"amount":8634.069811,"timestamp":1770295341611,"change":0,"changeRate":0,"amplitude":0.000645},"delay":0,"changeRate":0.0019379844961239896,"floatShares":113999999,"shares":113999999,"eps":-0.359451,"marketStatus":"盘前交易","change":0.03,"latestTime":"02-05 07:56:14 EST","open":15.48,"high":15.59,"low":15.47,"amount":69506003.258068,"amplitude":0.007752,"askPrice":15.51,"askSize":18,"bidPrice":15.49,"bidSize":1982,"shortable":3,"etf":0,"ttmEps":-0.359451,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770301800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1077166800000,"exchange":"NASDAQ","adjPreClose":15.51,"preHourTrading":{"tag":"盘前","latestPrice":15.51,"preClose":15.51,"latestTime":"07:42 EST","volume":557,"amount":8634.069811,"timestamp":1770295341611,"change":0,"changeRate":0,"amplitude":0.000645},"postHourTrading":{"tag":"盘后","latestPrice":15.4946,"preClose":15.51,"latestTime":"18:02 EST","volume":163440,"amount":2534951.27,"timestamp":1770246137568,"change":-0.0154,"changeRate":-0.000993,"amplitude":0.000993},"volumeRatio":2.33513730943478,"impliedVol":0.0509,"impliedVolPercentile":0.016},"requestUrl":"/m/hq/s/DVAX","defaultTab":"news","newsList":[{"id":"1161897285","title":"德纳维制药：特定情形下协议终止 赛诺菲将支付1.168亿美元反向解约金","url":"https://stock-news.laohu8.com/highlight/detail?id=1161897285","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161897285?lang=zh_cn&edition=full","pubTime":"2025-12-29 20:35","pubTimestamp":1767011749,"startTime":"0","endTime":"0","summary":"根据最新披露的条款，若德纳维制药（Dynavax）与赛诺菲（Sanofi）的合作协议因特定情形提前终止，赛诺菲需向德纳维支付高达1.168亿美元的反向终止费用。这一条款为合作关系的稳定性提供了重要保障。\n该反向解约金机制旨在保护德纳维的核心利益，确保其在潜在合作变动中获得实质性补偿。双方协议的详细情形说明，仅当满足预设条件时，此项费用才会被触发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DVAX"],"gpt_icon":0},{"id":"1115094623","title":"德纳维制药股价上涨38.6%至15.43美元，因法国制药公司赛诺菲拟以约22亿美元收购该公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1115094623","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115094623?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:34","pubTimestamp":1766586854,"startTime":"0","endTime":"0","summary":"德纳维制药股价上涨38.6%至15.43美元，因法国制药公司赛诺菲拟以约22亿美元收购该公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b31cda120fef942502fc01c1d2275ab4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DVAX"],"gpt_icon":0},{"id":"2593773214","title":"生物制药股Dynavax Technologies盘前大涨40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593773214","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593773214?lang=zh_cn&edition=full","pubTime":"2025-12-24 21:20","pubTimestamp":1766582400,"startTime":"0","endTime":"0","summary":"生物制药股Dynavax Technologies（DVAX）周三盘前大涨40%，此前赛诺菲（Sanofi）表示将以约22亿美元的股权价值收购Dynavax。Dynavax是一家疫苗公司，拥有成人乙型肝炎疫苗，并拥有一款具有差异化优势的带状疱疹候选疫苗。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-24/doc-inhcxizf4284978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["DVAX","BK4139","SINA"],"gpt_icon":0},{"id":"1158284226","title":"盘前｜DVAX暴涨38%，SIDU涨超14%，英特尔遇利空一度跌5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158284226","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158284226?lang=zh_cn&edition=full","pubTime":"2025-12-24 20:35","pubTimestamp":1766579740,"startTime":"0","endTime":"0","summary":"美股三大指数期货在盘前交易时段微跌。","market":"us","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"da3a316f50963ae42eb2c852a91d8114","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","INTC","SIDU"],"gpt_icon":1},{"id":"1166263568","title":"异动解读 | 赛诺菲22亿美元收购德纳维制药，后者盘前飙涨37.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166263568","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166263568?lang=zh_cn&edition=full","pubTime":"2025-12-24 18:30","pubTimestamp":1766572220,"startTime":"0","endTime":"0","summary":"德纳维制药（DVAX）今日盘前股价大涨37.56%，引发市场广泛关注。消息面上，法国制药巨头赛诺菲宣布将以每股15.50美元的现金价格收购德纳维制药，总交易价值约22亿美元。这一报价较德纳维制药周二收盘价溢价39%，直接推动了股价的飙升。通过此次收购，赛诺菲将获得德纳维制药已在美国上市的乙肝疫苗及处于早期试验阶段的带状疱疹疫苗，进一步强化其在成人疫苗领域的布局。该交易预计将于2026年第一季度完成，赛诺菲表示不会影响其2025年财务指引。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b31cda120fef942502fc01c1d2275ab4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVAX"],"gpt_icon":0},{"id":"2593473907","title":"德纳维制药美股盘前飙涨近38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593473907","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593473907?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:23","pubTimestamp":1766568217,"startTime":"0","endTime":"0","summary":"德纳维制药美股盘前飙涨近38%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512243600802127.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600802127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1193781365","title":"盘前异动｜DVAX、SIDU暴涨，UiPath迎利好，房多多涨6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193781365","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193781365?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:13","pubTimestamp":1766567617,"startTime":"0","endTime":"0","summary":"美股三大指数期货在盘前交易时段微跌。","market":"us","thumbnail":"https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b31cda120fef942502fc01c1d2275ab4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIDU","DUO","DVAX"],"gpt_icon":1},{"id":"1159825792","title":"德纳维制药股价在盘前交易中上涨37.7%至15.30美元，因法国制药公司赛诺菲拟以15.50美元每股收购该公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1159825792","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159825792?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:09","pubTimestamp":1766567380,"startTime":"0","endTime":"0","summary":"德纳维制药股价在盘前交易中上涨37.7%至15.30美元，因法国制药公司赛诺菲拟以15.50美元每股收购该公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b31cda120fef942502fc01c1d2275ab4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DVAX"],"gpt_icon":0},{"id":"1173918492","title":"赛诺菲斥资22亿美元收购德纳维制药，拓展疫苗业务版图","url":"https://stock-news.laohu8.com/highlight/detail?id=1173918492","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173918492?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:05","pubTimestamp":1766567137,"startTime":"0","endTime":"0","summary":"此项收购有望于2026年第一季度完成。","market":"us","thumbnail":"https://static.tigerbbs.com/b3f880628b60889f8f14e6438b5d8f36","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/b3f880628b60889f8f14e6438b5d8f36"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b31cda120fef942502fc01c1d2275ab4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX"],"gpt_icon":0},{"id":"1175074906","title":"赛诺菲以每股15.50美元的现金价格收购Dynavax所有流通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1175074906","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175074906?lang=zh_cn&edition=full","pubTime":"2025-12-24 14:20","pubTimestamp":1766557223,"startTime":"0","endTime":"0","summary":"12月24日，Dynavax夜盘涨近8%！赛诺菲以每股15.50美元的现金价格收购Dynavax公司的所有流通股。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b31cda120fef942502fc01c1d2275ab4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY","DVAX","BK5011"],"gpt_icon":0},{"id":"1186165748","title":"美股疫苗股大跌，FDA 官员提及新冠疫苗与年轻男性心脏疾病有关联","url":"https://stock-news.laohu8.com/highlight/detail?id=1186165748","media":"老虎资讯综合","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186165748?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:25","pubTimestamp":1764635137,"startTime":"0","endTime":"0","summary":"在疫情期间，Prasad 因反对疫苗强制措施以及对新冠疫苗引发心肌炎风险的关注而在网上获得追随者。其他研究则发现，新冠感染导致心肌炎的风险高于接种疫苗。辉瑞和 BioNTech 共同研发了新冠疫苗 Comirnaty。两家公司均研发并销售新冠 mRNA 疫苗。这并非 Prasad 首次推动与 mRNA 新冠疫苗相关的变更。这位 FDA 官员还呼吁为疫苗临床试验设定不同的终点指标。","market":"us","thumbnail":"https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f5a0c542474fbfdd95db309645c9c3a7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"美股疫苗股大跌，FDA 官员提及新冠疫苗与年轻男性心脏疾病有关联","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","BNTX","MRNA","PFE"],"gpt_icon":1},{"id":"2581753005","title":"德纳维制药盘中异动 股价大涨5.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581753005","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581753005?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:31","pubTimestamp":1762439471,"startTime":"0","endTime":"0","summary":"北京时间2025年11月06日22时31分，德纳维制药股票出现异动，股价急速拉升5.53%。截至发稿，该股报10.87美元/股，成交量6.755万股，换手率0.06%，振幅2.33%。德纳维制药股票所在的制药行业中，整体涨幅为0.06%。德纳维制药公司简介：Dynavax Technologies Corp 是一家生物制药公司，专注于通过 Toll 样受体刺激来利用人体先天和适应性免疫反应的力量。消息层面，截至22时31分，《威廉博莱维持德纳维制药买入评级》资讯为影响德纳维制药的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110622311197586029&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110622311197586029&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1198474248","title":"德纳维制药 - Z-1018 显示与 Shingrix 类似的反应并具良好耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1198474248","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198474248?lang=zh_cn&edition=full","pubTime":"2025-10-22 04:02","pubTimestamp":1761076928,"startTime":"0","endTime":"0","summary":"德纳维制药 - Z-1018 显示与 Shingrix 类似的反应并具良好耐受性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1149499484","title":"德纳维制药发布2025年Idweek上带状疱疹疫苗候选药物第1/2阶段试验第1部分的积极顶线数据，并宣布启动试验第2部分","url":"https://stock-news.laohu8.com/highlight/detail?id=1149499484","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149499484?lang=zh_cn&edition=full","pubTime":"2025-10-22 04:01","pubTimestamp":1761076871,"startTime":"0","endTime":"0","summary":"德纳维制药发布2025年Idweek上带状疱疹疫苗候选药物第1/2阶段试验第1部分的积极顶线数据，并宣布启动试验第2部分。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1174829488","title":"德纳维制药盘前涨7.7%，研究显示其带状疱疹疫苗免疫反应与葛兰素史克产品相当","url":"https://stock-news.laohu8.com/highlight/detail?id=1174829488","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174829488?lang=zh_cn&edition=full","pubTime":"2025-08-21 20:10","pubTimestamp":1755778244,"startTime":"0","endTime":"0","summary":"德纳维制药盘前涨7.7%，研究显示其带状疱疹疫苗免疫反应与葛兰素史克产品相当","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064927863.SGD","LU1481600234.SGD","LU0289739699.SGD","LU0985481810.HKD","LU0971552673.USD","LU1487256676.USD","LU1228905540.USD","LU1400636574.HKD","DVAX","LU1302929846.USD","LU1098665638.USD","LU0058720904.USD","LU0321505439.SGD","LU0225771236.USD","LU0203345920.USD","LU0971552830.HKD","LU0211331839.USD","LU1481599808.USD","IE00BWDBJ516.SGD","LU0203347892.USD","LU1400636657.SGD","LU1670756490.USD","LU0109981661.USD","LU0306806265.USD","IE0034235071.USD","LU1035777561.USD","LU1046248800.SGD","BK4139","LU0306807586.USD","IE00BQJZX424.USD","LU0225284248.USD","LU1015430645.USD","LU0575583348.USD","LU1202635105.USD","LU1400636491.USD","GSK.UK","LU1645745479.HKD","LU0545562505.USD","LU0321505868.SGD","BK5011","LU1228905037.USD"],"gpt_icon":0},{"id":"1183570094","title":"德纳维制药宣布带状疱疹疫苗1/2期临床试验取得积极顶线结果，支持其同类最佳疫苗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1183570094","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183570094?lang=zh_cn&edition=full","pubTime":"2025-08-21 20:02","pubTimestamp":1755777768,"startTime":"0","endTime":"0","summary":"德纳维制药宣布其带状疱疹疫苗1/2期临床试验取得积极的顶线结果，这些数据支持该疫苗具备同类最佳产品的潜在特性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1115331889","title":"德纳维制药：针对70岁及以上成人的Z-1018最佳剂量1/2期试验第二部分预计下半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1115331889","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115331889?lang=zh_cn&edition=full","pubTime":"2025-08-21 20:00","pubTimestamp":1755777624,"startTime":"0","endTime":"0","summary":"德纳维制药宣布，该公司针对70岁及以上成人群体的Z-1018药物1/2期临床试验第二部分预计将在下半年启动。此次试验将采用最佳剂量进行测试。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1124972261","title":"德纳维制药Z-1018试验显示注射后不良反应低于Shingrix","url":"https://stock-news.laohu8.com/highlight/detail?id=1124972261","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124972261?lang=zh_cn&edition=full","pubTime":"2025-08-21 20:00","pubTimestamp":1755777624,"startTime":"0","endTime":"0","summary":"德纳维制药宣布，在Z-1018临床试验中，其疫苗产品显示出比Shingrix更低的预期局部和全身注射后不良反应。这一试验结果表明，德纳维制药的疫苗候选产品在安全性方面可能具有优势，注射后引发的局部反应和全身性反应均较Shingrix为低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1159423422","title":"Dynavax Technologies：1/2期临床试验第一阶段显示Z-1018耐受性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1159423422","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159423422?lang=zh_cn&edition=full","pubTime":"2025-08-21 20:00","pubTimestamp":1755777617,"startTime":"0","endTime":"0","summary":"Dynavax Technologies：1/2期临床试验第一阶段显示Z-1018耐受性良好，具有良好的安全性表现","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DVAX"],"gpt_icon":0},{"id":"2513475690","title":"德纳维制药2024财年实现净利润27.31百万美元，同比增加527.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513475690","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513475690?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:01","pubTimestamp":1740326471,"startTime":"0","endTime":"0","summary":"2月24日，德纳维制药公布财报，公告显示公司2024财年净利润为27.31百万美元，同比增加527.39%；其中营业收入为2.77亿美元，同比增加19.40%，每股基本收益为0.21美元。从资产负债表来看，德纳维制药总负债3.89亿美元，其中短期债务4.18百万美元，资产负债比为2.54，流动比率为0.11。机构评级：截至2025年2月24日，当前有4家机构对德纳维制药目标价做出预测，其中目标均价为25.25美元，其中最低目标价为12.00美元，最高目标价为33.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000141abd9c7e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000141abd9c7e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DVAX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dynavax.com","stockEarnings":[{"period":"1week","weight":0.0019},{"period":"1month","weight":0.0065},{"period":"3month","weight":0.4113},{"period":"6month","weight":0.5015},{"period":"1year","weight":0.1931},{"period":"ytd","weight":0.0085}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.0769},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.0063}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Dynavax Technologies Corporation于1996年8月29日在加利福尼亚州双螺旋结构公司的名下注册成立，1999年9月更名为 Dynavax 技术公司。该公司于2000年在特拉华州重组。该公司是一家完全集成的生物制药公司，专注于通过Toll样受体（“TLR”）刺激来利用人体先天和适应性免疫反应的力量。他们的第一个商业产品HEPLISAV-B（乙型肝炎疫苗（重组型），佐剂化）于2017年11月获得美国食品和药物管理局（“FDA”）批准用于预防所有已知乙型肝炎亚型引起的感染病毒在18岁以上的成人。他们于2018年1月开始商业运送HEPLISAV-B。他们的开发工作主要集中在刺激先天性免疫反应，与其他免疫调节剂联合治疗癌症。他们的主要研究免疫肿瘤产品是SD-101，目前正在进行阶段2临床研究评估，DV281进行阶段1安全性研究。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.002421},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.02656},{"month":3,"riseRate":0.409091,"avgChangeRate":-0.007392},{"month":4,"riseRate":0.318182,"avgChangeRate":-0.006058},{"month":5,"riseRate":0.5,"avgChangeRate":0.022333},{"month":6,"riseRate":0.5,"avgChangeRate":0.023462},{"month":7,"riseRate":0.545455,"avgChangeRate":0.057705},{"month":8,"riseRate":0.454545,"avgChangeRate":0.040776},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.02771},{"month":10,"riseRate":0.5,"avgChangeRate":-0.003182},{"month":11,"riseRate":0.590909,"avgChangeRate":0.044257},{"month":12,"riseRate":0.545455,"avgChangeRate":0.144696}],"exchange":"NASDAQ","name":"德纳维制药","nameEN":"Dynavax"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"德纳维制药(DVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供德纳维制药(DVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"德纳维制药,DVAX,德纳维制药股票,德纳维制药股票老虎,德纳维制药股票老虎国际,德纳维制药行情,德纳维制药股票行情,德纳维制药股价,德纳维制药股市,德纳维制药股票价格,德纳维制药股票交易,德纳维制药股票购买,德纳维制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"德纳维制药(DVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供德纳维制药(DVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}